Literature DB >> 1418644

Hodgkin's disease.

D Kaufman1, D L Longo.   

Abstract

Entities:  

Mesh：

Year:  1992        PMID： 1418644     DOI： 10.1016/1040-8428(92)90021-h

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN： 1040-8428            Impact factor:   6.312


× No keyword cloud information.
  6 in total

1.  Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells.

Authors:  R C Bargou; F Emmerich; D Krappmann; K Bommert; M Y Mapara; W Arnold; H D Royer; E Grinstein; A Greiner; C Scheidereit; B Dörken
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

Review 2.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

3.  "First do no harm" and the importance of prediction in oncology.

Authors:  Dainius Characiejus; Jasmina Hodzic; John J L Jacobs
Journal:  EPMA J       Date:  2010-07-17       Impact factor: 6.543

4.  Assessment of the prognostic impact of the Epstein-Barr virus-encoded latent membrane protein-1 expression in Hodgkin's disease.

Authors:  M Glavina-Durdov; J Jakic-Razumovic; V Capkun; P Murray
Journal:  Br J Cancer       Date:  2001-05-04       Impact factor: 7.640

5.  Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity.

Authors:  Michael Hinz; Petra Lemke; Ioannis Anagnostopoulos; Christine Hacker; Daniel Krappmann; Stephan Mathas; Bernd Dörken; Martin Zenke; Harald Stein; Claus Scheidereit
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

6.  Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.

Authors:  R C Bargou; M Y Mapara; C Zugck; P T Daniel; M Pawlita; H Döhner; B Dörken
Journal:  J Exp Med       Date:  1993-05-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.